Aclaris Therapeutics, Inc. Income (Loss) from Continuing Operations before Income Taxes, Domestic
Aclaris Therapeutics, Inc. (ACRS) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$64.92 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-02-26
- Aclaris Therapeutics, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$64.92M.
- Aclaris Therapeutics, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$132.06M.
- Aclaris Therapeutics, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$88.85M.
- Aclaris Therapeutics, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$86.91M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | -$64.92M 10-K · filed 2026-02-26 |
| 2024-12-31 | -$132.06M 10-K · filed 2026-02-26 |
| 2023-12-31 | -$88.85M 10-K · filed 2025-02-27 |
| 2022-12-31 | -$86.91M 10-K · filed 2024-02-27 |
| 2021-12-31 | -$90.86M 10-K · filed 2024-02-27 |
| 2020-12-31 | -$51.22M 10-K · filed 2023-02-23 |
| 2019-12-31 | -$161.19M 10-K · filed 2022-02-24 |
| 2018-12-31 | -$132.47M 10-K · filed 2021-02-25 |
| 2017-12-31 | -$63.66M 10-K · filed 2020-02-25 |
| 2016-12-31 | -$40.60M 10-K · filed 2019-03-18 |
| 2015-12-31 | -$11.82M 10-K · filed 2018-03-12 |
| 2014-12-31 | -$8.52M 10-K · filed 2017-03-15 |
| 2013-12-31 | -$5.24M 10-K · filed 2016-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |